Africa Large Volume Parenterals (LVP) Market

Africa Large Volume Parenterals (LVP) Market Overview:

The Africa large volume parenterals (LVP) market was valued at $662 million in 2017, and is expected to reach $1,133 million by 2024, growing at a CAGR of 7.9% from 2018 to 2024. In terms of volume, the market garnered 291,095 thousand units in 2017, and is expected to reach 582,780 thousand units by 2024, growing with a CAGR of 10.4% from 2018 to 2024.

The growth of the Africa large volume parenterals market is driven by rise in prevalence of chronic diseases such as cancer, HIV, and other non-communicable diseases; rapid surge in number of surgeries; and rise in risk of malnutrition. However, preference for enteral route of drug administration of therapeutic & nutritional needs and high risk of infection/allergic reaction during a parenteral administration are expected to impede the market growth. Conversely, upsurge in demand for palliative care services in Africa is expected to offer opportunities for market expansion during the forecast period.

Africa Large Volume Parenterals Market Segmentation

The Africa large volume parenterals market is segmented on the basis of treatment type, route of administration, capacity, and country. On the basis of treatment type, the market is classified into fluid balance injections, therapeutic injections, and nutritious injections. Depending on route of administration, it is fragmented into intravenous, intramuscular, subcutaneous, and other routes. LVP are commercially available in 100 ml, 250 ml, 500 ml, 1000 ml, and 2000 ml bottles. Country wise, the market is analyzed across South Africa, Zimbabwe, Namibia, and rest of Africa.

Segment review

Fluid balance injection is the most commonly used treatment type, owing its wide applications such as fluid resuscitation, routine maintenance, replacement, and redistribution. Fluid resuscitation refers to the restoration of circulation to vital organs after loss of intravascular fluids due to bleeding, plasma loss, or excessive external fluid & electrolyte loss. Parenteral preparations are required by patients who cannot meet their normal fluid or electrolyte needs by oral/enteral routes. These patients need to undergo IV therapy for routine maintenance of bodily fluids and electrolytes. In addition, LVP may be needed for internal fluid distribution changes in case of edema or abnormal fluid handling by the organ systems. Fluid redistribution is required in patients who are critically ill, septic, with major cardiac, liver or renal comorbidity, or after a major surgery.

Based on route of administration, the market is fragmented into intravenous, intramuscular, subcutaneous, and other routes. Intravenous (IV) route is the most commonly used route, and serves as the fastest way to deliver large volume parenterals, as the drug is easily carried throughout the body with the help of circulation.

Furthermore, the market is analyzed for volume of large volume parenterals by capacity, i.e. 100 ml, 250 ml, 500 ml, 1000 ml, and 2000 ml bottles.

Snapshot of South Africa large volume parenterals market

South Africa has one of the most advanced palliative care systems in Africa, as it has an extensive network of hospice organizations that provide care to people suffering from chronic and life-threatening illnesses. For instance, palliative care is required in the end stage of cancer, lung diseases, diabetes, and cardiac diseases. In addition, rise in prevalence of non-communicable diseases is expected to drive the market growth. However, according to the South African Health News Service, most of the palliative care facilities in South Africa focus on cancer and HIV patients as compared to other conditions. Thus, South African healthcare organizations are expected to expand their palliative care facilities for patients suffering from other non-communicable or life-threatening disorders, which would further propel the growth of the market.

The key local players within Africa large volume parenterals market include Abacus Parenteral Drugs Limited, Erongo Med, Datlabs Private Limited, Addis Pharmaceuticals Factory PLC, Pharmacure PLC, Mascareignes Pharmaceutical Manufacturing Co. Ltd. (operates as a subsidiary of Parenteral Drug (India) Ltd.), and Adcock Ingram Holdings Ltd.

Key Benefits

• The study provides an in-depth analysis of the market with current trends and future estimations to elucidate the imminent investment pockets.
• It offers a quantitative analysis from 2017 to 2023, which is expected to enable the stakeholders to capitalize on prevailing market opportunities.
• Analysis by route of administration helps to understand the various routes for administration of parenteral drugs within the body.
• Comprehensive analysis of major countries within Africa is provided to determine the prevailing opportunities.
• Key players are profiled, and their strategies are analyzed thoroughly to understand the competitive outlook of the market.

 Africa Large Volume Parenterals (LVP) Market Report Highlights